Health Care • Biotechnology: Pharmaceutical Preparations
$3.77 ▲ +0.02
(+0.53%)
MKT CAP: $288.0M • VOL: 1.62M
52W L $3 52W H $16
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
FULC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$84.8M | -$21.9M | -$110.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$74.9M | -$9.7M | -$97.3M |
| EBITDA (Normalized) | -$84.5M | -$21.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$60.1M | -$2.2M | -$91.0M |
| Capital Expenditures (CapEx) | $314.0K | $278.0K | — |
| Free Cash Flow (FCF) | -$60.4M | -$2.5M | -$91.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -44.2% | -9.4% | — |
| Cash & Short-Term Equivalents | $197.5M | $58.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $349.0M | $243.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FULC.